Clinical trial
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
NCT00388089 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00388089 |
|---|---|
| Title | Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study of Weekly Bortezomib (VELCADE, PS-341) and Weekly Topotecan (HYCAMTIN) in Solid Tumor Patients With an Emphasis on Small Cell Lung Cancer (SCLC) |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | bortezomib, topotecan hydrochloride, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Dec 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Oct 13, 2006 |
| Last update posted | Jun 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: